ScinoPharm Taiwan, Ltd. (1789.TW)
TWD 21.85
(-1.35%)
TWD 21.85
(-1.35%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -3.32 Billion TWD | 8.19% |
| 2022 | -3.61 Billion TWD | -2.65% |
| 2021 | -3.52 Billion TWD | -1.31% |
| 2020 | -3.47 Billion TWD | -41.16% |
| 2019 | -2.46 Billion TWD | 11.71% |
| 2018 | -2.79 Billion TWD | -25.82% |
| 2017 | -2.21 Billion TWD | -15.48% |
| 2016 | -1.92 Billion TWD | -203.68% |
| 2015 | -632.39 Million TWD | 2.55% |
| 2014 | -648.97 Million TWD | 59.4% |
| 2013 | -1.59 Billion TWD | 42.3% |
| 2012 | -2.77 Billion TWD | 15.89% |
| 2011 | -3.29 Billion TWD | -72.87% |
| 2010 | -1.9 Billion TWD | -1892.21% |
| 2009 | -95.63 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -3.55 Billion TWD | -7.16% |
| 2024 Q2 | -3.55 Billion TWD | 0.16% |
| 2023 Q1 | -3.74 Billion TWD | -3.6% |
| 2023 Q3 | -3.34 Billion TWD | 6.23% |
| 2023 Q4 | -3.32 Billion TWD | 0.71% |
| 2023 Q2 | -3.56 Billion TWD | 4.82% |
| 2023 FY | -3.32 Billion TWD | 8.19% |
| 2022 Q4 | -3.61 Billion TWD | -0.57% |
| 2022 Q2 | -3.71 Billion TWD | -4.92% |
| 2022 Q1 | -3.54 Billion TWD | -0.59% |
| 2022 FY | -3.61 Billion TWD | -2.65% |
| 2022 Q3 | -3.59 Billion TWD | 3.29% |
| 2021 Q2 | -3.5 Billion TWD | -1.98% |
| 2021 Q4 | -3.52 Billion TWD | -11.08% |
| 2021 Q1 | -3.43 Billion TWD | 1.3% |
| 2021 FY | -3.52 Billion TWD | -1.31% |
| 2021 Q3 | -3.17 Billion TWD | 9.39% |
| 2020 Q4 | -3.47 Billion TWD | -12.5% |
| 2020 Q2 | -3.19 Billion TWD | -13.54% |
| 2020 Q1 | -2.81 Billion TWD | -14.37% |
| 2020 FY | -3.47 Billion TWD | -41.16% |
| 2020 Q3 | -3.09 Billion TWD | 3.38% |
| 2019 Q3 | -2.26 Billion TWD | 0.35% |
| 2019 Q4 | -2.46 Billion TWD | -8.87% |
| 2019 Q2 | -2.27 Billion TWD | -1.05% |
| 2019 Q1 | -2.24 Billion TWD | 19.46% |
| 2019 FY | -2.46 Billion TWD | 11.71% |
| 2018 Q4 | -2.79 Billion TWD | -20.67% |
| 2018 FY | -2.79 Billion TWD | -25.82% |
| 2018 Q1 | -2.19 Billion TWD | 1.08% |
| 2018 Q2 | -2.23 Billion TWD | -1.92% |
| 2018 Q3 | -2.31 Billion TWD | -3.42% |
| 2017 Q1 | -1.97 Billion TWD | -2.96% |
| 2017 FY | -2.21 Billion TWD | -15.48% |
| 2017 Q4 | -2.21 Billion TWD | -7.65% |
| 2017 Q3 | -2.06 Billion TWD | -8.08% |
| 2017 Q2 | -1.9 Billion TWD | 3.6% |
| 2016 FY | -1.92 Billion TWD | -203.68% |
| 2016 Q3 | -1.36 Billion TWD | -11.87% |
| 2016 Q2 | -1.22 Billion TWD | -48.63% |
| 2016 Q1 | -823.33 Million TWD | -30.19% |
| 2016 Q4 | -1.92 Billion TWD | -40.29% |
| 2015 Q1 | -611.24 Million TWD | 5.81% |
| 2015 FY | -632.39 Million TWD | 2.55% |
| 2015 Q4 | -632.39 Million TWD | -298.19% |
| 2015 Q3 | -158.81 Million TWD | 82.74% |
| 2015 Q2 | -919.9 Million TWD | -50.5% |
| 2014 Q3 | -178.38 Million TWD | 84.85% |
| 2014 Q4 | -648.97 Million TWD | -263.8% |
| 2014 FY | -648.97 Million TWD | 59.4% |
| 2014 Q2 | -1.17 Billion TWD | 31.6% |
| 2014 Q1 | -1.72 Billion TWD | -7.71% |
| 2013 Q3 | -1.99 Billion TWD | 24.13% |
| 2013 FY | -1.59 Billion TWD | 42.3% |
| 2013 Q1 | -3.01 Billion TWD | -8.95% |
| 2013 Q2 | -2.62 Billion TWD | 13.07% |
| 2013 Q4 | -1.59 Billion TWD | 19.69% |
| 2012 Q4 | -2.77 Billion TWD | -20.29% |
| 2012 FY | -2.77 Billion TWD | 15.89% |
| 2012 Q2 | -2.97 Billion TWD | 8.16% |
| 2012 Q1 | -3.23 Billion TWD | 1.74% |
| 2012 Q3 | -2.3 Billion TWD | 22.52% |
| 2011 Q3 | -3.19 Billion TWD | -59.09% |
| 2011 Q4 | -3.29 Billion TWD | -3.1% |
| 2011 Q2 | -2 Billion TWD | 0.0% |
| 2011 FY | -3.29 Billion TWD | -72.87% |
| 2010 FY | -1.9 Billion TWD | -1892.21% |
| 2010 Q4 | -1.9 Billion TWD | 0.0% |
| 2009 FY | -95.63 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Grape King Bio Ltd | -4.62 Billion TWD | 28.219% |
| Standard Chem & Pharm CO., LTD. | -954.74 Million TWD | -247.782% |
| Maywufa Company Ltd. | 264.18 Million TWD | 1356.854% |
| Lotus Pharmaceutical Co., Ltd. | 9.81 Billion TWD | 133.834% |
| LIWANLI Innovation Co., Ltd. | -244.02 Million TWD | -1260.7% |
| YungShin Global Holding Corporation | -247.5 Million TWD | -1241.579% |
| PhytoHealth Corporation | -34.64 Million TWD | -9485.234% |
| SCI Pharmtech, Inc. | 100.41 Million TWD | 3406.632% |
| Formosa Laboratories, Inc. | 2.53 Billion TWD | 230.808% |
| PharmaEssentia Corporation | -18.46 Billion TWD | 82.019% |
| Bora Pharmaceuticals Co., LTD. | 1.95 Billion TWD | 269.708% |